You all are moping around here like there’s no catalyst until the Rett excellence is approved. If the Alzheimer’s trial data is favorable this stock takes off like a rocket. Rett is fine but peanuts compared to the real moneymaker in the eyes of big Pharma. The bidding war will be to say the least, intense. We’ve waited a long time for this. Buckle up.
News 
Market Data 
Discover 
